Treatment with the small-molecule arginase inhibitor CB-1158 was shown to reduce tumor growth in several mouse models of cancer by increasing the number of tumor-infiltrating CD8+ T-cells and NK cells, and production of TH1-associated inflammatory cytokines39. Here, CD8A is linked to neoplasm.